{"owner": "ArrayExpress Uploader", "pop_total": 0, "species": "human", "factors": [{"GSE1743GSM30431": {"ClinicalTreatment": "cyclosporin A, mycophenolate mofetil, prednisone"}}, {"GSE1743GSM30442": {"ClinicalTreatment": "sirolimus, mycophenolate mofetil, prednisone"}}, {"GSE1743GSM30431": {"ClinicalTreatment": "cyclosporin A, mycophenolate mofetil, prednisone"}}, {"GSE1743GSM30442": {"ClinicalTreatment": "sirolimus, mycophenolate mofetil, prednisone"}}, {"GSE1743GSM30431": {"ClinicalTreatment": "cyclosporin A, mycophenolate mofetil, prednisone"}}, {"GSE1743GSM30431": {"ClinicalTreatment": "cyclosporin A, mycophenolate mofetil, prednisone"}}, {"GSE1743GSM30442": {"ClinicalTreatment": "sirolimus, mycophenolate mofetil, prednisone"}}, {"GSE1743GSM30431": {"ClinicalTreatment": "cyclosporin A, mycophenolate mofetil, prednisone"}}, {"GSE1743GSM30431": {"ClinicalTreatment": "cyclosporin A, mycophenolate mofetil, prednisone"}}, {"GSE1743GSM30431": {"ClinicalTreatment": "cyclosporin A, mycophenolate mofetil, prednisone"}}, {"GSE1743GSM30442": {"ClinicalTreatment": "sirolimus, mycophenolate mofetil, prednisone"}}, {"GSE1743GSM30431": {"ClinicalTreatment": "cyclosporin A, mycophenolate mofetil, prednisone"}}, {"GSE1743GSM30431": {"ClinicalTreatment": "cyclosporin A, mycophenolate mofetil, prednisone"}}, {"GSE1743GSM30442": {"ClinicalTreatment": "sirolimus, mycophenolate mofetil, prednisone"}}, {"GSE1743GSM30442": {"ClinicalTreatment": "sirolimus, mycophenolate mofetil, prednisone"}}, {"GSE1743GSM30431": {"ClinicalTreatment": "cyclosporin A, mycophenolate mofetil, prednisone"}}, {"GSE1743GSM30442": {"ClinicalTreatment": "sirolimus, mycophenolate mofetil, prednisone"}}, {"GSE1743GSM30431": {"ClinicalTreatment": "cyclosporin A, mycophenolate mofetil, prednisone"}}, {"GSE1743GSM30431": {"ClinicalTreatment": "cyclosporin A, mycophenolate mofetil, prednisone"}}, {"GSE1743GSM30442": {"ClinicalTreatment": "sirolimus, mycophenolate mofetil, prednisone"}}, {"GSE1743GSM30442": {"ClinicalTreatment": "sirolimus, mycophenolate mofetil, prednisone"}}, {"GSE1743GSM30431": {"ClinicalTreatment": "cyclosporin A, mycophenolate mofetil, prednisone"}}, {"GSE1743GSM30442": {"ClinicalTreatment": "sirolimus, mycophenolate mofetil, prednisone"}}, {"GSE1743GSM30442": {"ClinicalTreatment": "sirolimus, mycophenolate mofetil, prednisone"}}, {"GSE1743GSM30431": {"ClinicalTreatment": "cyclosporin A, mycophenolate mofetil, prednisone"}}, {"GSE1743GSM30442": {"ClinicalTreatment": "sirolimus, mycophenolate mofetil, prednisone"}}, {"GSE1743GSM30431": {"ClinicalTreatment": "cyclosporin A, mycophenolate mofetil, prednisone"}}, {"GSE1743GSM30442": {"ClinicalTreatment": "sirolimus, mycophenolate mofetil, prednisone"}}, {"GSE1743GSM30431": {"ClinicalTreatment": "cyclosporin A, mycophenolate mofetil, prednisone"}}, {"GSE1743GSM30431": {"ClinicalTreatment": "cyclosporin A, mycophenolate mofetil, prednisone"}}, {"GSE1743GSM30431": {"ClinicalTreatment": "cyclosporin A, mycophenolate mofetil, prednisone"}}, {"GSE1743GSM30431": {"ClinicalTreatment": "cyclosporin A, mycophenolate mofetil, prednisone"}}, {"GSE1743GSM30442": {"ClinicalTreatment": "sirolimus, mycophenolate mofetil, prednisone"}}, {"GSE1743GSM30442": {"ClinicalTreatment": "sirolimus, mycophenolate mofetil, prednisone"}}, {"GSE1743GSM30442": {"ClinicalTreatment": "sirolimus, mycophenolate mofetil, prednisone"}}, {"GSE1743GSM30431": {"ClinicalTreatment": "cyclosporin A, mycophenolate mofetil, prednisone"}}, {"GSE1743GSM30442": {"ClinicalTreatment": "sirolimus, mycophenolate mofetil, prednisone"}}, {"GSE1743GSM30442": {"ClinicalTreatment": "sirolimus, mycophenolate mofetil, prednisone"}}, {"GSE1743GSM30431": {"ClinicalTreatment": "cyclosporin A, mycophenolate mofetil, prednisone"}}, {"GSE1743GSM30431": {"ClinicalTreatment": "cyclosporin A, mycophenolate mofetil, prednisone"}}, {"GSE1743GSM30442": {"ClinicalTreatment": "sirolimus, mycophenolate mofetil, prednisone"}}], "id": 1810, "ownerprofile_id": "arrayexpress_sid", "platform": 3, "summary_wrapped": "Background: Despite significant improvements in short-term kidney transplant survival, comparable increases in 5 and 10-year outcomes...", "pubmed_id": 15476476, "geo_gse_id": "E-GEOD-1743", "owner_profile": "/profile/8773/arrayexpressuploader", "factor_count": 1, "sample_count": 41, "tags": ["kidney", "serum"], "lastmodified": "Dec.12, 2014", "is_default": false, "geo_gds_id": "", "slug": "transcription-profiling-of-human-kidneys-from-chro", "geo_id_plat": "E-GEOD-1743_A-AFFY-33", "name": "Transcription profiling of human kidneys from chronic allograft nephropathy patients treated with either cyclosporin or sirolimus immunosuppression regimes", "created": "Jun.20, 2014", "summary": "Background: Despite significant improvements in short-term kidney transplant survival, comparable increases in 5 and 10-year outcomes have not been achieved. Chronic allograft nephropathy (CAN) is a major cause of late graft loss. Toxic nephropathy and inadequate long-term immunosuppression are possible factors. We performed a randomized prospective trial comparing calcineurin inhibitor (CNI)-free to CNI-based immunosuppression to determine the impact on renal function, structure, and gene expression. Methods: Sixty-one kidney recipients received mycophenolate mofetil (MMF), and prednisone (P). Randomized patients received concentration-controlled sirolimus or cyclosporine. Two years post-transplant 55 patients underwent renal function studies, 48 (87%) underwent transplant biopsies; all classified by Banff scoring and 41 by DNA microarrays. Findings:  Comparing sirolimus/MMF/P to cyclosporine/MMF/P at two years, there was a significantly lower serum creatinine (1.35 vs. 1.81 mg/dl; p=0.008), significantly higher Cockroft-Gault glomerular filtration rate (GFR) (80.4 vs. 63.4 cc/min; p=0.008), iothalamate GFR (60.6 vs. 49.2 cc/min; p= 0.018), and Banff 0 (normal) biopsies (66.6 vs. 20.8%; p=0.013).  Regression analysis of calculated GFR\u2019s from 1 to 36 months yielded a positive slope for sirolimus of 3.36 ml/min/year, and a negative slope for cyclosporine of \u20131.58 ml/min/year (p=0.008). Gene expression profiles of kidney biopsies with higher Banff CAN scores confirmed significant up regulation of genes responsible for immune/inflammation and fibrosis/tissue remodeling. Interpretation:  At two years the sirolimus-treated patients have better renal transplant function, a diminished prevalence of CAN, and down regulated expression of genes responsible for the progression of CAN. All may provide for an alternative natural history with improved graft survival.", "source": "http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-1743", "sample_source": "http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-1743/samples/"}